Insys Therapeuti (NASDAQ:INSY) is one of today’s best performing penny stocks, up 35.6% to $0.46 on 2.6x average daily volume. Insys Therapeuti has traded 8.1 million shares thus far today, vs. average volume of 3.1 million shares per day. The stock has outperformed the Dow (35.6% to the Dow’s 0.3%) and outperformed the S&P 500 (35.6% to the S&P’s 0.3%) during today’s trading.
Insys Therapeuti (NASDAQ:INSY) has potential upside of 1,895.7% based on a current price of $0.46 and analysts’ consensus price target of $9.20. The stock should find initial resistance at its 50-day moving average (MA) of $2.85 and further resistance at its 200-day MA of $5.48.
Over the past year, Insys Therapeuti has traded in a range of $0.14 to $11.65 and is now at $0.46, 229% above that low. In the last five trading sessions, the 50-day moving average (MA) has fallen 8.1% while the 200-day MA has slid 2%.
Insys Therapeutics, Inc. develops cancer support drugs. The Company support care candidates include a fast-acting sublingual spray for cancer pain and a dronabinol product used to treat chemotherapy-induced nausea and vomiting and to stimulate appetite in AIDS patients.
SmarTrend is monitoring the recent change of momentum in Insys Therapeuti. Please refer to our Company Overview for the results of our proprietary technical indicators that have been scanning shares of Insys Therapeuti in search of a potential trend change.
Write to SmarTrend at firstname.lastname@example.org
SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.MySmarTrend.com
Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at: http://www.MySmarTrend.com/signup